108 related articles for article (PubMed ID: 36152564)
21. Corrigendum to "Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1" [Canc. Lett. 385 (2017) 65-74].
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2022 Aug; 540():215739. PubMed ID: 35599097
[No Abstract] [Full Text] [Related]
22. Corrigendum to "SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission" [Canc. Lett. 547 (2022) 215871].
Wang M; Wei R; Li G; Bi HL; Jia Z; Zhang M; Pang M; Li X; Ma L; Tang Y
Cancer Lett; 2022 Nov; 549():215923. PubMed ID: 36166936
[No Abstract] [Full Text] [Related]
23. Corrigendum to "The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer" [Canc. Lett. 423 (2018) 36-46].
Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S
Cancer Lett; 2018 Sep; 431():244. PubMed ID: 29754994
[No Abstract] [Full Text] [Related]
24. Corrigendum to "Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B" [Canc. Lett. 535 (2022) 215629].
Liu Y; Zhang Z; Gao X; Ma Q; Yu Z; Huang S
Cancer Lett; 2022 Jul; 539():215701. PubMed ID: 35527117
[No Abstract] [Full Text] [Related]
25. Corrigendum to "Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway" [Canc. Lett. 342 (2014) 150-158].
Zhao Z; Wu MS; Zou C; Tang Q; Lu J; Liu D; Wu Y; Yin J; Xie X; Shen J; Kang T; Wang J
Cancer Lett; 2021 Dec; 522():281. PubMed ID: 34561145
[No Abstract] [Full Text] [Related]
26. Corrigendum to "Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway" [Canc. Lett. (2023) 216142].
Zhang Y; Chen J; Mi D; Ling J; Li H; He P; Liu N; Chen Q; Chen Y; Huang L
Cancer Lett; 2023 Jul; 567():216195. PubMed ID: 37156646
[No Abstract] [Full Text] [Related]
27. Corrigendum to "Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer" [Canc. Lett. 459 (2019 Sep 10) 122-134].
Liu X; Lu Y; Xu Y; Hou S; Huang J; Wang B; Zhao J; Xia S; Fan S; Yu X; Du Y; Hou L; Li Z; Ding Z; An S; Huang B; Li L; Tang J; Ju J; Guan H; Song B
Cancer Lett; 2022 Jul; 539():215695. PubMed ID: 35501203
[No Abstract] [Full Text] [Related]
28. Corrigendum to 'ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2' [Canc. Lett. 427 (2018) 9-17].
Luo Q; Wu X; Zhang Y; Shu T; Ding F; Chen H; Zhao P; Chang W; Zhu X; Liu Z
Cancer Lett; 2021 Feb; 498():243. PubMed ID: 33342532
[No Abstract] [Full Text] [Related]
29. Corrigendum to "Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22" [Canc. Lett. 340 (1) (Oct 28, 2013) 72-81].
Tang H; Kong Y; Guo J; Tang Y; Xie X; Yang L; Su Q; Xie X
Cancer Lett; 2021 Feb; 498():253. PubMed ID: 33032849
[No Abstract] [Full Text] [Related]
30. Corrigendum to "Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway" [Canc. Lett. (2009) 282(2) 167-76 doi:10.1016/j.canlet.2009.03.003].
Bhui K; Prasad S; George J; Shukla Y
Cancer Lett; 2020 Jun; 480():48. PubMed ID: 32035655
[No Abstract] [Full Text] [Related]
31. Corrigendum to "Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM." [Canc. Lett. 449 (2019) 31-44].
Xie R; Chen X; Chen Z; Huang M; Dong W; Gu P; Zhang J; Zhou Q; Dong W; Han J; Wang X; Li H; Huang J; Lin T
Cancer Lett; 2021 Mar; 500():292-293. PubMed ID: 33390287
[No Abstract] [Full Text] [Related]
32. Corrigendum to "MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways" [Canc. Lett. 337 (2013) 226-236].
Bao L; Yan Y; Xu C; Ji W; Shen S; Xu G; Zeng Y; Sun B; Qian H; Chen L; Wu M; Chen J; Su C
Cancer Lett; 2020 Mar; 473():198-199. PubMed ID: 31926781
[No Abstract] [Full Text] [Related]
33. Corrigendum to "Targeting autophagy in cancer stem cells as an anticancer therapy" [Canc. Lett. 393 (2017) 33-39].
Lei Y; Zhang D; Yu J; Dong H; Zhang J; Yang S
Cancer Lett; 2018 Mar; 416():149. PubMed ID: 29307478
[No Abstract] [Full Text] [Related]
34. Corrigendum to "UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation" [Canc. Lett. 494 (2020) 121-131].
Yin H; Wang X; Zhang X; Zeng Y; Xu Q; Wang W; Zhou F; Zhou Y
Cancer Lett; 2022 Sep; 543():215792. PubMed ID: 35718664
[No Abstract] [Full Text] [Related]
35. Corrigendum to "NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma" [Canc. Lett. 476 (2020) 48-56].
Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
Cancer Lett; 2021 Feb; 499():2. PubMed ID: 32563702
[No Abstract] [Full Text] [Related]
36. Corrigendum to "MLKL contributes to shikonin-induced glioma cell necroptosis via promotion of chromatinolysis" [Canc. Lett. 467 (2019) 58-71].
Ding Y; He C; Lu S; Wang X; Wang C; Wang L; Zhang J; Piao M; Chi G; Luo Y; Sai K; Ge P
Cancer Lett; 2020 Mar; 472():183. PubMed ID: 31917020
[No Abstract] [Full Text] [Related]
37. Corrigendum to "B4GALT3 up-regulation by miR-27a contributes to the oncogenic activity in human cervical cancer cells." [Canc. Lett. 375 (2016) 284-292].
Sun Y; Yang X; Liu M; Tang H
Cancer Lett; 2020 Nov; 493():16-18. PubMed ID: 32823018
[No Abstract] [Full Text] [Related]
38. Corrigendum to "Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells" [Canc. Lett. 412 (2018) 297-307].
Le HT; Nguyen HT; Min HY; Hyun SY; Kwon S; Lee Y; Le THV; Lee J; Park JH; Lee HY
Cancer Lett; 2018 Jun; 424():136. PubMed ID: 29573834
[No Abstract] [Full Text] [Related]
39. Corrigendum to "FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway" [Canc. Lett. 363 (2015) 166-175].
Haque A; Rahman MA; Fuchs JR; Chen Z; Khuri FR; Shin DM; Amin ARMR
Cancer Lett; 2021 Feb; 498():249-250. PubMed ID: 33092912
[No Abstract] [Full Text] [Related]
40. Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells.
Zhao C; Yang L; Zhou F; Yu Y; Du X; Xiang Y; Li C; Huang X; Xie C; Liu Z; Lin J; Wang L; Liang G; Cui R
Oncogene; 2020 May; 39(20):3997-4013. PubMed ID: 32242147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
